home technology voting sponsoring glossary contact imprint


Mosaiques has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of cardiovascular, renal, and urogenital diseases. Furthermore, diagnostic tests for additional indications, such as Alzheimer´s disease, pancreatic cancer, and nephrotoxic effects of drugs are in development. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a risk-free and painless procedure. Mosaiques utilizes high resolution capillary electrophoresis coupled mass spectrometry (CE-MS technology), which enables the separation of body fluids in less than one hour. Proprietary software affords the analysis of huge amounts of data within minutes.

The overall principle of this ground-breaking technology is the fact that proteins are indispensable for the function of cells and organs, as well as for all communication inside the body. They also catalyze chemical reactions and protect the body against pathogens. Thousands of proteins and peptides are involved in these processes, forming a distinct pattern, which changes with disease. Mosaiques identifies up to 6,000 of such proteins and polypeptides and subsequently generates disease specific patterns. This vast wealth of information facilitates accurate diagnosis of diseases and enables effective therapy prior to serious organ damage. VIDEO (Animation  of Technology)

In focus: Urine is the specimen of choice for clinical proteome analysis, since urine can be obtained in large quantities from a non-invasive procedure and contains thousands of proteins and polypeptides that hold specific information on the (patho)physiology of each individual. In addition, urine is much more stable in its composition compared to blood, but contains not a lesser prominent variety of informative biomolecules, which are indicative of the patient’s state of health.
To further promote and enable research and development in the area of urinary proteomics, we are making this database publicly available. By using this large collection of data, scientists worldwide are enabled to evaluate urinary biomarkers "in silico".
Diagnosis of bladder and prostate cancer, chronic renal diseases, diabetic nephropathy, Graft-versus-Host Disease, ureteropelvic junction obstruction in newborn, and infarct risk is already marketed in Germany through the subsidiary DiaPat GmbH. The combination of the above mentioned indications enables the comprehensive and non-invasive examination of the patient’s state of health via the Health-Checkup system. DiaPat’s polypeptide pattern technology has been proven in multiple blinded clinical studies on over 14,000 qualified patient samples from different pathological alterations:
For the first time you have the chance to vote which disease mosaiques will do a research on. It is your choise which disease is the most important one in your eyes. The highest ranged disease out of the voting mosaiques will investigate all with support out of “Vote4health” Sponsoring.


Prospects of Diagnostic Pattern

  1. Early detection of disease
  2. Differential detection of disease
  3. Therapy Evaluation
  4. Monitoring
  5. Therapy Control

Area of application Diagnostic Pattern

Early diagnosis


Therapy Evaluation



Diabetic Nephropathy

The following tests for different diseases are available

  • Bladder Cancer
  • Prostate Cancer
  • Chronic Nephropathies
  • Diabetic Nephropathy
  • Cardiovascular Diseases
  • DiaPat Health-Check
  • GvHD
  • Ureteropelvic Junction Obstruction in Neonates


Plethora of possible applications in the near future

  • Kidney Cancer
  • Alzheimer’s Disease
  • Kaposi’s Sarcoma
  • and many more…




© 2009 Vote for Health